Special Stock Report: Daiichi Sankyo (5.78% → 3.83%) by Capital Research and others.

Filer: Capital Research and Management Company Filing Date and Time: February 6, 2026, 09:48 Document Filed: Amendment Report (Special Case Target Shares) (Cover Page = Amendment Report No. 14) Reporting Obligation Trigger Date: January 30, 2026 Reason for Filing Amendment Report: The holding ratio of shares decreased by more than 1% Issuer: Daiichi Sankyo Co., Ltd. <4568> Summary

Jiji PressFeb 5 19:51 ET

3 Asian Stocks Estimated To Be Trading At Up To 49.1% Below Intrinsic Value

Yahoo FinanceFeb 5 17:34 ET

Bayer and Daiichi Sankyo Advance New Prostate Cancer Combo in Early-Stage Trial

TipRanksFeb 4 11:31 ET

DS3790 Enters Clinical Development as First DXd ADC in Hematology From Industry-Leading ADC Portfolio of Daiichi Sankyo

BusinesswireFeb 4 07:00 ET

List of Converted Securities (Part 1) [List of Securities with Parabolic Signal Conversion]

List of Buy-Conversion Securities by Market: Code Security Name Closing Price SAR TSE Prime <1414> Shobond 1435 1369 <1417> Mirait One 3835 3654 <1721> Comsys HD 4939 4758 <1802> Obayashi 3700 3415 <1803> Shimizu Corp. 2906 2662 <1812> Kajima 6553 6251 <1820> Nishimatsu Construction 5925 5630 <1835> Tohoku Railroad

Fisco JapanFeb 3 17:50 ET

DATROWAY (Datopotamab Deruxtecan-dlnk) Granted Priority Review in the US as 1st-line Treatment for Patients With Metastatic Triple-negative Breast Cancer Who Are Not Candidates for Immunotherapy

BusinesswireFeb 3 07:00 ET